[
  {
    "id": 1,
    "name": "Dr. Sarah Chen",
    "title": "Director of Toxicology",
    "company": "Vertex Pharmaceuticals",
    "company_type": "Large Pharma",
    "location": "Cambridge, MA",
    "hq_location": "Boston, MA",
    "email": "s.chen@vertexpharm.com",
    "linkedin": "linkedin.com/in/sarahchen-tox",
    "funding_status": "Public",
    "recent_publication": "Drug-Induced Liver Injury: A 3D Hepatic Spheroid Approach (2024)",
    "publication_keywords": ["DILI", "hepatic spheroids", "3D culture"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "AACR 2023"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 2,
    "name": "Dr. Michael Torres",
    "title": "Head of Preclinical Safety",
    "company": "Foghorn Therapeutics",
    "company_type": "Series C Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "mtorres@foghorntx.com",
    "linkedin": "linkedin.com/in/michaeltorres",
    "funding_status": "Series C ($200M)",
    "recent_publication": "Novel In Vitro Models for Hepatotoxicity Screening (2023)",
    "publication_keywords": ["hepatotoxicity", "in vitro", "screening"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 20,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 3,
    "name": "Dr. Emma Williams",
    "title": "VP of Drug Safety",
    "company": "Moderna",
    "company_type": "Large Pharma",
    "location": "Boston, MA",
    "hq_location": "Cambridge, MA",
    "email": "ewilliams@modernatx.com",
    "linkedin": "linkedin.com/in/emmawilliams-safety",
    "funding_status": "Public",
    "recent_publication": null,
    "publication_keywords": [],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "ISSX 2023"],
    "scores": {
      "scientific_intent": 0,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 4,
    "name": "Dr. James Liu",
    "title": "Senior Scientist, Hepatic Biology",
    "company": "Takeda",
    "company_type": "Large Pharma",
    "location": "San Diego, CA",
    "hq_location": "Cambridge, MA",
    "email": "james.liu@takeda.com",
    "linkedin": "linkedin.com/in/jamesliu-hepatic",
    "funding_status": "Public",
    "recent_publication": "3D Liver Organoids for DILI Prediction (2024)",
    "publication_keywords": ["3D organoids", "DILI", "liver"],
    "uses_invitro": true,
    "conference_attendance": ["AACR 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 5,
    "name": "Dr. Anna Kowalski",
    "title": "Director of Safety Assessment",
    "company": "Arcus Biosciences",
    "company_type": "Series B Biotech",
    "location": "Hayward, CA",
    "hq_location": "Hayward, CA",
    "email": "akowalski@arcusbio.com",
    "linkedin": "linkedin.com/in/annakowalski",
    "funding_status": "Series B ($150M)",
    "recent_publication": "Microphysiological Systems in Drug-Induced Cardiotoxicity (2023)",
    "publication_keywords": ["MPS", "cardiotoxicity"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2023"],
    "scores": {
      "scientific_intent": 20,
      "role_fit": 30,
      "company_intent": 20,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 6,
    "name": "Dr. Robert Schmidt",
    "title": "Head of Investigative Toxicology",
    "company": "Novartis",
    "company_type": "Large Pharma",
    "location": "Basel, Switzerland",
    "hq_location": "Basel, Switzerland",
    "email": "robert.schmidt@novartis.com",
    "linkedin": "linkedin.com/in/robertschmidt-tox",
    "funding_status": "Public",
    "recent_publication": "Advancing NAMs for Regulatory Toxicology (2024)",
    "publication_keywords": ["NAMs", "regulatory", "toxicology"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "EUROTOX 2023"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 7,
    "name": "Dr. Priya Patel",
    "title": "Principal Scientist, ADMET",
    "company": "Recursion Pharmaceuticals",
    "company_type": "Series D Biotech",
    "location": "Salt Lake City, UT",
    "hq_location": "Salt Lake City, UT",
    "email": "ppatel@recursion.com",
    "linkedin": "linkedin.com/in/priyapatel-admet",
    "funding_status": "Series D ($450M)",
    "recent_publication": null,
    "publication_keywords": [],
    "uses_invitro": true,
    "conference_attendance": ["SLAS 2024"],
    "scores": {
      "scientific_intent": 0,
      "role_fit": 20,
      "company_intent": 20,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 8,
    "name": "Dr. David Park",
    "title": "Associate Director, Hepatic Safety",
    "company": "Genentech",
    "company_type": "Large Pharma",
    "location": "South San Francisco, CA",
    "hq_location": "South San Francisco, CA",
    "email": "parkd@gene.com",
    "linkedin": "linkedin.com/in/davidpark-hepatic",
    "funding_status": "Public (Roche)",
    "recent_publication": "Human iPSC-Derived Hepatocytes for DILI Studies (2024)",
    "publication_keywords": ["iPSC", "hepatocytes", "DILI"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "ISSCR 2023"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 9,
    "name": "Dr. Catherine Moore",
    "title": "Senior Director, Preclinical",
    "company": "Beam Therapeutics",
    "company_type": "Series B Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "cmoore@beamtx.com",
    "linkedin": "linkedin.com/in/catherinemoore-preclinical",
    "funding_status": "Series B ($180M)",
    "recent_publication": "Base Editing Safety: Lessons from 3D Models (2023)",
    "publication_keywords": ["base editing", "safety", "3D models"],
    "uses_invitro": true,
    "conference_attendance": ["ASGCT 2024"],
    "scores": {
      "scientific_intent": 35,
      "role_fit": 25,
      "company_intent": 20,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 10,
    "name": "Dr. Thomas Brown",
    "title": "Director of In Vitro Pharmacology",
    "company": "AbbVie",
    "company_type": "Large Pharma",
    "location": "North Chicago, IL",
    "hq_location": "North Chicago, IL",
    "email": "thomas.brown@abbvie.com",
    "linkedin": "linkedin.com/in/thomasbrown-invitro",
    "funding_status": "Public",
    "recent_publication": "High-Throughput 3D Liver Models for Drug Discovery (2024)",
    "publication_keywords": ["high-throughput", "3D liver", "drug discovery"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "SLAS 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 11,
    "name": "Dr. Jennifer Adams",
    "title": "VP of Toxicology",
    "company": "Sarepta Therapeutics",
    "company_type": "Public Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "jadams@sarepta.com",
    "linkedin": "linkedin.com/in/jenniferadams-tox",
    "funding_status": "Public",
    "recent_publication": "Gene Therapy Safety Assessment Using Organoids (2023)",
    "publication_keywords": ["gene therapy", "safety", "organoids"],
    "uses_invitro": true,
    "conference_attendance": ["ASGCT 2024", "SOT 2023"],
    "scores": {
      "scientific_intent": 35,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 12,
    "name": "Dr. Marcus Johnson",
    "title": "Head of DMPK",
    "company": "Relay Therapeutics",
    "company_type": "Series C Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "mjohnson@relaytx.com",
    "linkedin": "linkedin.com/in/marcusjohnson-dmpk",
    "funding_status": "Series C ($400M)",
    "recent_publication": null,
    "publication_keywords": [],
    "uses_invitro": true,
    "conference_attendance": ["ISSX 2024"],
    "scores": {
      "scientific_intent": 0,
      "role_fit": 20,
      "company_intent": 20,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 13,
    "name": "Dr. Lisa Zhang",
    "title": "Director of Drug Metabolism",
    "company": "Alnylam Pharmaceuticals",
    "company_type": "Public Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "lzhang@alnylam.com",
    "linkedin": "linkedin.com/in/lisazhang-metabolism",
    "funding_status": "Public",
    "recent_publication": "siRNA Hepatotoxicity: 3D Culture Insights (2024)",
    "publication_keywords": ["siRNA", "hepatotoxicity", "3D culture"],
    "uses_invitro": true,
    "conference_attendance": ["OTS 2024", "SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 25,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 14,
    "name": "Dr. Richard Evans",
    "title": "Senior Toxicologist",
    "company": "Merck",
    "company_type": "Large Pharma",
    "location": "West Point, PA",
    "hq_location": "Rahway, NJ",
    "email": "richard.evans@merck.com",
    "linkedin": "linkedin.com/in/richardevans-tox",
    "funding_status": "Public",
    "recent_publication": "Comparative Analysis of 2D vs 3D Hepatic Models (2024)",
    "publication_keywords": ["2D", "3D", "hepatic", "comparative"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 15,
    "name": "Dr. Sophie Martin",
    "title": "Head of Safety Pharmacology",
    "company": "GSK",
    "company_type": "Large Pharma",
    "location": "Stevenage, UK",
    "hq_location": "London, UK",
    "email": "sophie.martin@gsk.com",
    "linkedin": "linkedin.com/in/sophiemartin-safety",
    "funding_status": "Public",
    "recent_publication": "NAMs Integration in Early Drug Development (2024)",
    "publication_keywords": ["NAMs", "drug development", "safety"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "EUROTOX 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 16,
    "name": "Dr. Kevin O'Brien",
    "title": "Associate Scientist",
    "company": "Startup XYZ",
    "company_type": "Seed Stage",
    "location": "Austin, TX",
    "hq_location": "Austin, TX",
    "email": "kevin@startupxyz.com",
    "linkedin": "linkedin.com/in/kevinobrien",
    "funding_status": "Seed ($2M)",
    "recent_publication": null,
    "publication_keywords": [],
    "uses_invitro": false,
    "conference_attendance": [],
    "scores": {
      "scientific_intent": 0,
      "role_fit": 10,
      "company_intent": 5,
      "technographic": 0,
      "location": 0
    }
  },
  {
    "id": 17,
    "name": "Dr. Amanda Foster",
    "title": "Principal Investigator",
    "company": "Harvard Medical School",
    "company_type": "Academic",
    "location": "Boston, MA",
    "hq_location": "Boston, MA",
    "email": "afoster@hms.harvard.edu",
    "linkedin": "linkedin.com/in/amandafoster-pi",
    "funding_status": "NIH R01 Grant",
    "recent_publication": "Organ-on-Chip for DILI Mechanistic Studies (2024)",
    "publication_keywords": ["organ-on-chip", "DILI", "mechanistic"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "TERMIS 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 25,
      "company_intent": 10,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 18,
    "name": "Dr. Chris Kim",
    "title": "Director of NAMs Development",
    "company": "AstraZeneca",
    "company_type": "Large Pharma",
    "location": "Gaithersburg, MD",
    "hq_location": "Cambridge, UK",
    "email": "chris.kim@astrazeneca.com",
    "linkedin": "linkedin.com/in/chriskim-nams",
    "funding_status": "Public",
    "recent_publication": "New Approach Methodologies in Respiratory Toxicology (2024)",
    "publication_keywords": ["NAMs", "respiratory", "toxicology"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "RTC 2024"],
    "scores": {
      "scientific_intent": 35,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 19,
    "name": "Dr. Maria Gonzalez",
    "title": "Senior Research Scientist",
    "company": "Pfizer",
    "company_type": "Large Pharma",
    "location": "Groton, CT",
    "hq_location": "New York, NY",
    "email": "maria.gonzalez@pfizer.com",
    "linkedin": "linkedin.com/in/mariagonzalez-research",
    "funding_status": "Public",
    "recent_publication": "3D Hepatospheres for Drug-Drug Interaction Studies (2023)",
    "publication_keywords": ["hepatospheres", "DDI", "3D"],
    "uses_invitro": true,
    "conference_attendance": ["ISSX 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 25,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 20,
    "name": "Dr. Brian Taylor",
    "title": "VP of Preclinical Development",
    "company": "Blueprint Medicines",
    "company_type": "Public Biotech",
    "location": "Cambridge, MA",
    "hq_location": "Cambridge, MA",
    "email": "btaylor@blueprintmedicines.com",
    "linkedin": "linkedin.com/in/briantaylor-preclinical",
    "funding_status": "Public",
    "recent_publication": "Kinase Inhibitor Hepatotoxicity Assessment (2024)",
    "publication_keywords": ["kinase inhibitor", "hepatotoxicity"],
    "uses_invitro": true,
    "conference_attendance": ["AACR 2024", "SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 21,
    "name": "Dr. Nicole Harris",
    "title": "Head of Liver Biology",
    "company": "Aligos Therapeutics",
    "company_type": "Series B Biotech",
    "location": "South San Francisco, CA",
    "hq_location": "South San Francisco, CA",
    "email": "nharris@aligos.com",
    "linkedin": "linkedin.com/in/nicoleharris-liver",
    "funding_status": "Series B ($225M)",
    "recent_publication": "Primary Human Hepatocyte 3D Cultures for HBV Research (2024)",
    "publication_keywords": ["hepatocyte", "3D", "HBV"],
    "uses_invitro": true,
    "conference_attendance": ["AASLD 2024", "HBV Forum 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 20,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 22,
    "name": "Dr. Steven Wright",
    "title": "Director of Toxicological Sciences",
    "company": "Eli Lilly",
    "company_type": "Large Pharma",
    "location": "Indianapolis, IN",
    "hq_location": "Indianapolis, IN",
    "email": "wright_steven@lilly.com",
    "linkedin": "linkedin.com/in/stevenwright-toxsci",
    "funding_status": "Public",
    "recent_publication": "AI-Driven DILI Prediction Using 3D Models (2024)",
    "publication_keywords": ["AI", "DILI", "3D models", "prediction"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024", "SLAS 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 23,
    "name": "Dr. Laura Sanchez",
    "title": "Staff Scientist, ADME-Tox",
    "company": "Gilead Sciences",
    "company_type": "Large Pharma",
    "location": "Foster City, CA",
    "hq_location": "Foster City, CA",
    "email": "laura.sanchez@gilead.com",
    "linkedin": "linkedin.com/in/laurasanchez-admetox",
    "funding_status": "Public",
    "recent_publication": null,
    "publication_keywords": [],
    "uses_invitro": true,
    "conference_attendance": ["ISSX 2023"],
    "scores": {
      "scientific_intent": 0,
      "role_fit": 25,
      "company_intent": 15,
      "technographic": 15,
      "location": 10
    }
  },
  {
    "id": 24,
    "name": "Dr. Andrew Clark",
    "title": "Head of Drug Safety",
    "company": "Incyte",
    "company_type": "Public Biotech",
    "location": "Wilmington, DE",
    "hq_location": "Wilmington, DE",
    "email": "aclark@incyte.com",
    "linkedin": "linkedin.com/in/andrewclark-drugsafety",
    "funding_status": "Public",
    "recent_publication": "Hepatocyte-Based Assays for JAK Inhibitor Safety (2024)",
    "publication_keywords": ["hepatocyte", "JAK inhibitor", "safety"],
    "uses_invitro": true,
    "conference_attendance": ["SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  },
  {
    "id": 25,
    "name": "Dr. Rachel Green",
    "title": "Associate Director, Hepatotoxicity",
    "company": "Regeneron",
    "company_type": "Large Pharma",
    "location": "Tarrytown, NY",
    "hq_location": "Tarrytown, NY",
    "email": "rachel.green@regeneron.com",
    "linkedin": "linkedin.com/in/rachelgreen-hepatotox",
    "funding_status": "Public",
    "recent_publication": "Liver Organoids for Antibody Drug Safety (2024)",
    "publication_keywords": ["liver organoids", "antibody", "safety"],
    "uses_invitro": true,
    "conference_attendance": ["PEGS 2024", "SOT 2024"],
    "scores": {
      "scientific_intent": 40,
      "role_fit": 30,
      "company_intent": 15,
      "technographic": 15,
      "location": 0
    }
  }
]
